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StrainsDual infections of influenza A and influenza B are rare events
that have been previously described.1 Such co-infections
have not been widely described or characterized as a result
of the previous widespread use of culture-based methods for
diagnosis and the heterotypic interference generated within
these models.2 We describe the use of molecular tools to
characterize a case of influenza A and influenza B co-infec-
tion in a specimen collected in the setting of a long-term care
facility with a respiratory outbreak from co-circulating influ-
enza A and influenza B.
The respiratory outbreak was declared by the local public
health department. Nasopharyngeal swabs were collected
from suspect patients. Specimens were tested by the BD
Directigen Flu A+B assay (Oakville, Ontario, Canada), and
cultured and tested for influenza A and B by direct fluores-
cence antibody (DFA) staining (Diagnostic Hybrids, Athens,
Ohio, USA). Real-time RT-PCR followed the Centers for Dis-
ease Control and Prevention, USA, protocols (Lindstrom,
2007, personal communication), with confirmation by strainTable 1 Characterization of influenza A and B in outbreak speci
Patient Rapid antigen Culture
1 Not detected Not detected
2 Influenza A;
Influenza B
Influenza A;
Influenza B
3 Influenza B Influenza B
4 Not detected Not detected
5 Not done Influenza B
6 Not done Not detected
1201-9712/$36.00. Crown Copyright # 2008 Published by Elsevier Ltd on be
doi:10.1016/j.ijid.2008.06.024analysis and characterization of antiviral resistance muta-
tions.3—9
Of six patients, two (patients 3 and 5) were influenza B
positive, one was influenza A positive (patient 1), and
one was positive for both influenza A and influenza B
(patient 2) (Table 1). All influenza B sequences (patients
2, 3 and 5) most closely resembled influenza B/Florida/
4/2006. All influenza A sequences (patients 1 and 2)
most closely resembled A/Brisbane/10/2007 (H3N2)
(Table 1). All A/Brisbane/10/2007 (H3N2) strains carried
the S31N mutation associated with adamantane resistance,
but not mutations E119 V, I222T or R292K, which are
associated with oseltamivir resistance/decreased
susceptibility. None of the B/Florida/4/2006 strains
carried mutations E116D/A/V/GV, R149K and R291K,
again associated with oseltamivir resistance/decreased
susceptibility.
Until themechanisms of dual infection are understood, we
believe that instances of dual infections should be taken
seriously by both clinicians and public health workers. One
reason for this concern is the well-described resistance of
influenza A and influenza B to antiviral agents, including the
inherent resistance of influenza B to adamantanes, the near
complete resistance of current influenza A (H3N2) strains to
adamantanes and the growing resistance of some influenza A
(H1N1) strains to oseltamivir.10 In conclusion, we believe that
molecular techniques are a powerful tool that enables labor-
atorians to extensively characterize circulating strains of
influenza, including co-infections, without the use of cul-
ture-based methods.
Conflict of interest: No conflict of interest to declare.
Funding: None.
Ethical Approval: N/A.mens
PCR Strain
Influenza A A/Brisbane/10/2007 (H3N2)
Influenza A;
Influenza B
A/Brisbane/10/2007 (H3N2);
B/Florida/4/2006
Influenza B B/Florida/4/2006
Not detected Not done
Influenza B B/Florida/4/2006
Not detected Not done
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